Axonal Degeneration in AD: The Contribution of Aβ and Tau
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder, affecting around 35 million people worldwide. Despite enormous efforts dedicated to AD research over decades, there is still no cure for the disease. Misfolding and accumulation of Aβ and tau proteins in the brain constitute a defining signature of AD neuropathology, and mounting evidence has documented a link between aggregation of these proteins and neuronal dysfunction. In this context, progressive axonal degeneration has been associated with early stages of AD and linked to Aβ and tau accumulation. As the axonal degeneration mechanism has been starting to be unveiled, it constitutes a promising target for neuroprotection in AD. A comprehensive understanding of the mechanism of axonal destruction in neurodegenerative conditions is therefore critical for the development of new therapies aimed to prevent axonal loss before irreversible neuronal death occurs in AD. Here, we review current evidence of the involvement of Aβ and tau pathologies in the activation of signaling cascades that can promote axonal demise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Geroscience: Linking Aging to Chronic Disease
Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.039 · Cited by 2,764
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382 · cited 1×
“Necroptosis Involvement in the Mechanism of Axonal Demise Mitochondrial dysfunction, ROS production, and intracellular calcium increase, which as mentioned above are key events that mediate axonal degeneration, have also been associated with activation of the necroptosis signaling pathway (Vandenabeele et al., 2010).”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 1×
“…| Volume 12 | Article 581767 the process of axonal degeneration, including mitochondrial dysfunction (Swerdlow, 2018; Albensi, 2019), oxidative stress (Butterfield and Boyd-Kimball, 2018; Cheignon et al., 2018) and calcium dyshomeostasis (Mata, 2018; Popugaeva et al., 2018; Wang and Zheng, 2019).”
BackgroundReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“Remarkably, the evidence indicates that accumulation of Aβ and tau is slow and that initiates more than two decades before clinical symptoms appear (Jack et al., 2009; Braak et al., 2011; Bateman et al., 2012; Villemagne et al., 2013), which has important diagnostic and therapeutic implications.”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“While most AD cases are sporadic, less than 5% of the cases are caused by mutations in the amyloid precursor protein (APP) gene or presenilin 1 or 2 genes, leading to excessive production and accumulation of amyloid-β peptide (Aβ; Citron et al., 1992; Hendriks et al., 1992; Mullan et al., 1992; Suzuki et al., 1994; Ha…”
BackgroundFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · cited 1×
“The first report describing tau pathology showed that neurofibrillary changes in the form of NFT and neuropil threads (NT) exhibit a characteristic distribution pattern affecting vulnerable brain regions such as the cerebral cortex and hippocampus (Braak and Braak, 1997).”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Numerous studies have demonstrated that these toxic structures do not act independently and that rather, the neurodegenerative process in AD depends on the interaction between both Aβ and tau (Götz et al., 2001; Lewis et al., 2001; Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007; Hurtado et al., 2010;…”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Genetic deletion of CypD suppressed Aβ-mediated activation of the p38/MAPK signaling pathway, reversed axonal mitochondrial alterations, improved synaptic function, and prevented synapse loss (Guo et al., 2013).”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“…cases are caused by mutations in the amyloid precursor protein (APP) gene or presenilin 1 or 2 genes, leading to excessive production and accumulation of amyloid-β peptide (Aβ; Citron et al., 1992; Hendriks et al., 1992; Mullan et al., 1992; Suzuki et al., 1994; Harvey et al., 2003; Goate, 2006).”
BackgroundThe importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses
Li, Z., Okamoto, K.-I., Hayashi, Y., & Sheng, M. (2004) · Cell · doi:10.1016/j.cell.2004.11.003 · Cited by 1,498 · cited 1×
“Mitochondria are required at pre- and postsynaptic terminals for the correct function of neurotransmission, as it has essential roles in ATP production and buffering synaptic calcium (Li et al., 2004; Sheng and Cai, 2012).”
BackgroundAn english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
The mitochondrial basis of aging
Sun, N., Youle, R. J., & Finkel, T. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.028 · Cited by 1,441
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Although deposition of Aβ and tau has been the center of AD drug development research, many clinical trials on Aβ and tau clearing have been conducted, with disappointing outcomes (Congdon and Sigurdsson, 2018; Huang et al., 2020).”
BackgroundJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060 · cited 1×
“Although genetic and pharmacological inhibition of UPS activity delays axon degeneration, overexpression of NMNAT1 alone can prevent axonal degeneration (Zhai et al., 2003; Araki et al., 2004).”
BackgroundHippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850 · cited 2×
“…| www.frontiersin.org 8 October 2020 | Volume 12 | Article 581767 the process of axonal degeneration, including mitochondrial dysfunction (Swerdlow, 2018; Albensi, 2019), oxidative stress (Butterfield and Boyd-Kimball, 2018; Cheignon et al., 2018) and calcium dyshomeostasis (Mata, 2018;…”
BackgroundKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“Progressive build-up of these abnormal aggregates is associated with synaptic disruption (Shankar et al., 2008; Koffie et al., 2009; Moreno et al., 2011; Zempel et al., 2013; Rajmohan and Reddy, 2017; Pickett et al., 2019) and neuronal loss (Kadowaki et al.”
BackgroundAxon degeneration mechanisms: Commonality amid diversity
Coleman, M. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1788 · Cited by 819 · cited 2×
“Accordingly, disruptions on this vital cellular process can eventually lead to axonal degeneration (Ferri et al., 2003; Coleman, 2005, 2011; Pigino et al., 2009; Kanaan et al., 2013).”
BackgroundThe pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Tau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790 · cited 2×
“Many reports have documented that significant decreases in NAD+ occur during aging (Lautrup et al., 2019; McReynolds et al., 2020) and supplementation of this metabolite has been suggested as a potential treatment for age-related diseases including AD (Braidy et al.”
BackgroundClinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · cited 1×
“…process in AD depends on the interaction between both Aβ and tau (Götz et al., 2001; Lewis et al., 2001; Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007; Hurtado et al., 2010; Ittner et al., 2010; Vossel et al., 2010; Nussbaum et al., 2012; Zempel et al., 2013; Wang et al., 2016).”
BackgroundAbsence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646
Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628 · cited 1×
“Although most research in AD has focused on the study of the loss of dendrites and synapses associated with Aβ pathology, as there is compelling evidence linking these alterations with cognitive decline (Davies et al., 1987; DeKosky and Scheff, 1990; Terry et al., 1991; Scheff et al., 2006; Bastrikova et al., 2008; Ja…”
BackgroundJawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623 · cited 1×
“…et al., 2009; Moreno et al., 2011; Zempel et al., 2013; Rajmohan and Reddy, 2017; Pickett et al., 2019) and neuronal loss (Kadowaki et al., 2005; Jawhar et al., 2012; DeVos et al., 2017; Fu et al., 2017), leading to atrophy of specific brain regions (Spires-Jones and Hyman, 2014; Ferreira et…”
BackgroundWidespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans
Johnson, V. E., Stewart, W., & Smith, D. H. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00513.x · Cited by 620
SARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561 · cited 2×
“In vivo evidence of the temporal course of Aβ-related axonal pathology underwent by different AD mouse models—using two-photon imaging—has revealed that the environment around plaques is not uniform and that rather, it promotes a continuous remodeling, suggesting that axonal dystrophies associated with Aβ plaques are…”
BackgroundDeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · cited 1×
“, 2019) and neuronal loss (Kadowaki et al., 2005; Jawhar et al., 2012; DeVos et al., 2017; Fu et al., 2017), leading to atrophy of specific brain regions (Spires-Jones and Hyman, 2014; Ferreira et al.”
BackgroundCritical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516
Necroptosis activation in Alzheimer's disease
Caccamo, A., Branca, C., Piras, I. S., Ferreira, E., Huentelman, M. J., Liang, W. S., Readhead, B., Dudley, J. T., Spangenberg, E. E., Green, K. N., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4608 · Cited by 482
Hou, Y., Lautrup, S., Cordonnier, S., Wang, Y., Croteau, D. L., Zavala, E., Zhang, Y., Moritoh, K., O’Connell, J. F., Baptiste, B. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718819115 · Cited by 472 · cited 1×
“Growing data from in vivo imaging studies have documented a relationship between such white matter abnormalities and Aβ deposition (Collins-Praino et al., 2014; Hoy et al., 2017; Schilling et al., 2018; Vipin et al., 2019; Weaver et al., 2019; Caballero et al., 2020).”
BackgroundEndogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472 · cited 1×
“The loss of NAD+ is suppressed in sterile alpha and TIR motif-containing 1 (SARM1) knockout (ko) axons both in vitro and in vivo, suggesting that SARM1 is a key mediator of axon destruction (Gerdts et al., 2013, 2015; Gilley et al., 2015).”
BackgroundPrion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427 · cited 1×
“Numerous studies have demonstrated that these toxic structures do not act independently and that rather, the neurodegenerative process in AD depends on the interaction between both Aβ and tau (Götz et al., 2001; Lewis et al., 2001; Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007; Hurtado et al., 2010;…”
BackgroundButterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
Autophagosome Biogenesis in Primary Neurons Follows an Ordered and Spatially Regulated Pathway
Maday, S., & Holzbaur, E. L. F. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.001 · Cited by 372
Neurons May Live for Decades with Neurofibrillary Tangles
Morsch, R., Simon, W., & Coleman, P. D. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199902000-00008 · Cited by 370
Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau
Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D., Schilling, B., Mavros, C., Masters, C. L., Volitakis, I., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000536 · Cited by 363
A local mechanism mediates NAD-dependent protection of axon degeneration
Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M. W., & He, Z. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504028 · Cited by 352
Sex differences in the association between AD biomarkers and cognitive decline
Initiative, F. T. A. N., Koran, M. E. I., Wagener, M., & Hohman, T. J. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9523-8 · Cited by 339
Proteasomal degradation of tau protein
David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327
Compartment-Specific Regulation of Autophagy in Primary Neurons
Maday, S., & Holzbaur, E. L. F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4401-15.2016 · Cited by 309 · cited 1×
“Axons depend on the constant remodeling of damaged proteins and organelles to maintain their correct functioning and connectivity (Maday and Holzbaur, 2016).”
BackgroundA dual leucine kinase–dependent axon self-destruction program promotes Wallerian degeneration
Miller, B. R., Press, C., Daniels, R. W., Sasaki, Y., Milbrandt, J., & DiAntonio, A. (2009) · Nature Neuroscience · doi:10.1038/nn.2290 · Cited by 301
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Thies, E., & Mandelkow, E.-M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4674-06.2007 · Cited by 293
Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia
Samieri, C., Perier, M.-C., Gaye, B., Proust-Lima, C., Helmer, C., Dartigues, J.-F., Berr, C., Tzourio, C., & Empana, J.-P. (2018) · JAMA · doi:10.1001/jama.2018.11499 · Cited by 293 · cited 2×
“The morphology of these irregular neuronal processes, which correspond to regions with cytoskeletal alteration and organelle accumulation, may change as the disease progresses (Vickers et al., 1996; Su et al., 1998; Woodhouse et al., 2009; Sanchez-Varo et al., 2012).”
BackgroundZempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283 · cited 2×
“…process in AD depends on the interaction between both Aβ and tau (Götz et al., 2001; Lewis et al., 2001; Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007; Hurtado et al., 2010; Ittner et al., 2010; Vossel et al., 2010; Nussbaum et al., 2012; Zempel et al., 2013; Wang et al., 2016).”
BackgroundSasaki, Y., Araki, T., & Milbrandt, J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2320-06.2006 · Cited by 269
Fu, H., Rodriguez, G. A., Herman, M., Emrani, S., Nahmani, E., Barrett, G., Figueroa, H. Y., Goldberg, E., Hussaini, S. A., & Duff, K. E. (2017) · Neuron · doi:10.1016/j.neuron.2016.12.023 · Cited by 264
Conforti, L., Tarlton, A., Mack, T. G. A., Mi, W., Buckmaster, E. A., Wagner, D., Perry, V. H., & Coleman, M. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11377 · Cited by 251
Hurtado, D. E., Molina-Porcel, L., Iba, M., Aboagye, A. K., Paul, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100346 · Cited by 222 · cited 2×
“Importantly, these results suggest that atrophy due to disruption of white matter fibers might contribute to memory decline (Kalus et al., 2006; Stoub et al., 2006; Rogalski et al., 2009; Ihara et al., 2010; Bozzali et al., 2011).”
BackgroundSanchez-Varo, R., Trujillo-Estrada, L., Sanchez-Mejias, E., Torres, M., Baglietto-Vargas, D., Moreno-Gonzalez, I., De Castro, V., Jimenez, S., Ruano, D., Vizuete, M., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0896-x · Cited by 222 · cited 1×
“Moreover, the overexpression of NMNAT3, which is predominantly located in mitochondria, confers axonal protection after injury (Sasaki et al., 2006).”
BackgroundFerri, A., Sanes, J. R., Coleman, M. P., Cunningham, J. M., & Kato, A. C. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00206-9 · Cited by 221
Targeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204 · cited 1×
“In the context of AD, different pathogenic pathways have been shown to contribute to axon demise, including calcium signaling imbalance, mitochondrial dysfunction, alterations in axonal transport, and increased oxidative stress (Bamburg and Bloom, 2009; Yu et al., 2009; Ye et al., 2012; Cioffi et al., 2019; Guo et al.…”
BackgroundGhoshal, N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8014 · Cited by 192
Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190
Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Salvadores, N., Sanhueza, M., Manque, P., & Court, F. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00451 · Cited by 182
Self-citationPickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., Jain, P., Dunnett, S., Sohrabi, S., Fjeldstad, M. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.044 · Cited by 179
Agosta, F., Vossel, K. A., Miller, B. L., Migliaccio, R., Bonasera, S. J., Filippi, M., Boxer, A. L., Karydas, A., Possin, K. L., & Gorno-Tempini, M. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812697106 · Cited by 178
Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner, M., Misgeld, T., & Coleman, M. P. (2009) · Brain · doi:10.1093/brain/awn312 · Cited by 177 · cited 5×
“, 2019), Aβ-related dystrophic axons are widespread in diseased brains and several studies suggest that they contribute to synaptic damage (Adalbert et al., 2009; Sanchez-Varo et al., 2012).”
BackgroundInfluentialTau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β
Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167
Yahata, N., Yuasa, S., & Araki, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4304-08.2009 · Cited by 154
Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations
Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149
Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress
Press, C., & Milbrandt, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0525-08.2008 · Cited by 137
Loreto, A., Hill, C. S., Hewitt, V. L., Orsomando, G., Angeletti, C., Gilley, J., Lucci, C., Sanchez-Martinez, A., Whitworth, A. J., Conforti, L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104678 · Cited by 131 · cited 1×
“…the dependence of NAD+ in this process, as well as the involvement of mitochondrial dysfunction and necroptosis activation (Barrientos et al., 2011; Osterloh et al., 2012; Neukomm et al., 2017; Hernández et al., 2018; Arrázola et al., 2019; Ko et al., 2020; Loreto et al., 2020; Oñate et al., 2020).”
BackgroundExpression of β-Amyloid Induced Age-Dependent Presynaptic and Axonal Changes in Drosophila
Zhao, X.-L., Wang, W.-A., Tan, J.-X., Huang, J.-K., Zhang, X., Zhang, B.-Z., Wang, Y.-H., YangCheng, H.-Y., Zhu, H.-L., Sun, X.-J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3699-09.2010 · Cited by 130 · cited 1×
“Thus, just as alterations in axonal transport can lead to amyloid pathology, there is also extensive evidence that Aβ itself can cause microtubulebased transport defects (Pigino et al., 2009; Zhao et al., 2010; Calkins and Reddy, 2011; Tang et al., 2012; Cruz et al., 2018; Zhang et al., 2018).”
BackgroundAxonal degeneration as a therapeutic target in the CNS
Lingor, P., Koch, J. C., Tönges, L., & Bähr, M. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1362-3 · Cited by 119
Louis, J. V., Martens, E., Borghgraef, P., Lambrecht, C., Sents, W., Longin, S., Zwaenepoel, K., Pijnenborg, R., Landrieu, I., Lippens, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018777108 · Cited by 112 · cited 1×
“On the other hand, the activity of PP2A, the main tau phosphatase, is reduced in AD brains, and the inhibition of PP2A activity in mice models of AD result in tau pathology and cognitive impairment (Wang et al., 2010; Louis et al., 2011; Braithwaite et al., 2012).”
BackgroundLjungberg, M. C., Ali, Y. O., Zhu, J., Wu, C.-S., Oka, K., Zhai, R. G., & Lu, H.-C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr492 · Cited by 107 · cited 3×
“Interestingly, in human AD brains as well as in rTg4510 mice, NMNAT2 expression is reduced, suggesting a possible mechanism by which tau pathology can contribute to axonal degeneration (Ljungberg et al., 2011; Ali et al., 2016).”
BackgroundAmyloid-beta and tau pathology following repetitive mild traumatic brain injury
Edwards, G., Moreno-Gonzalez, I., & Soto, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.123 · Cited by 96
Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease
LoBue, C., Wadsworth, H., Wilmoth, K., Clem, M., Hart, J., Womack, K. B., Didehbani, N., Lacritz, L. H., Rossetti, H. C., & Cullum, C. M. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1257069 · Cited by 90
van Hameren, G., Campbell, G., Deck, M., Berthelot, J., Gautier, B., Quintana, P., Chrast, R., & Tricaud, N. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0740-4 · Cited by 83
Collins-Praino, L. E., Francis, Y. I., Griffith, E. Y., Wiegman, A. F., Urbach, J., Lawton, A., Honig, L. S., Cortes, E., Vonsattel, J. P. G., Canoll, P. D., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0083-0 · Cited by 79
The ubiquitin proteasome system in synaptic and axonal degeneration
Korhonen, L., & Lindholm, D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200311091 · Cited by 72
Weaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
The Pathophysiology of Axonal Transport in Alzheimer's Disease
Vicario-Orri, E., Opazo, C. M., & Muñoz, F. J. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141080 · Cited by 41 · cited 1×
“Defects in axonal transport have been extensively studied in the context of AD and it has been suggested to have a causative role in the disease (Muresan and Muresan, 2009; Vicario-Orri et al., 2014).”
BackgroundShishido, H., Kishimoto, Y., Kawai, N., Toyota, Y., Ueno, M., Kubota, T., Kirino, Y., & Tamiya, T. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.066 · Cited by 38
Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model
Nishioka, C., Liang, H.-F., Barsamian, B., & Sun, S.-W. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.01.007 · Cited by 30
Cited by
White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution
Garnier‐Crussard, A., Cotton, F., Krolak‐Salmon, P., & Chételat, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13057 · Cited by 139
Decourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
Ali, D. G., Abner, E. L., Bahrani, A. A., El Khouli, R., Gold, B. T., Jiang, Y., Wilcock, D. M., & Jicha, G. A. (2023) · Brain Sciences · doi:10.3390/brainsci13020218 · Cited by 6
Gong, Z., Laporte, J. P., Guo, A. Y., Bilgel, M., Bae, J., Fox, N. Y., de Rouen, A., Zhang, N., Taranath, A., de Cabo, R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196638 · Cited by 7
“Impaired axonal transport, often due to mitochondrial dysfunction or the accumulation of toxic proteins like tau, leads to the accumulation of waste products and energy depletion, further exacerbating degeneration (46–48).”
Metadata
- Authors
- Salvadores, N., Gerónimo-Olvera, C., & Court, F. A.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-10-15
- Volume
- 12
- Pages
- 581767-581767
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W3093223082
- Cited by
- 96
- References
- 91
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.